IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Chen, Huan; Liu, Kai-yan; Xu, Lan-ping; Chen, Yu-hong; Han, Wei; Zhang, Xiao-hui; Wang, Yu; Qin, Ya-zhen; Liu, Yan-rong; Huang, Xiao-jun
关键词Haploidentical Hematopoietic stem cell transplantation Philadelphia chromosome Acute lymphoblastic leukemia Imatinib resistance
刊名BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
2015-06-01
DOI10.1016/j.bbmt.2015.02.009
21期:6页:1110-1116
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Hematology ; Immunology ; Transplantation
研究领域[WOS]Hematology ; Immunology ; Transplantation
关键词[WOS]VERSUS-HOST-DISEASE ; TERM-FOLLOW-UP ; TOTAL-BODY IRRADIATION ; ACUTE MYELOID-LEUKEMIA ; ADULT PATIENTS ; MARROW-TRANSPLANTATION ; IMATINIB ; CHEMOTHERAPY ; SURVIVAL ; COMBINATION
英文摘要

The role of haploidentical related allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is not clear. We aimed to investigate the long-term survival of Ph+ ALL patients who underwent haploidentical donor (HID)-HSCT and to analyze the factors influencing relapse and survival after allo-HSCT. The study population included Ph+ ALL patients who underwent haploidentical related allo-HSCT. Additionally, Ph+ ALL patients who underwent HLA-matched related donor (MRD) transplants during the same period were included to compare outcomes.,BCR-ABL transcript levels were analyzed by using real-time quantitative reverse transcription PCR. Clinical data from 139 Ph+ ALL patients who received allo-HSCT in our center were analyzed. Of these patients, 101 received HID transplants and 38 received MRD transplants. At a median follow-up of 36 months, 5-year disease-free survival (DFS) and overall survival (OS) rates in the HID transplant group were 65.8% and 74.0%, respectively. The 5-year cumulative incidence of relapse (CIR) and nonrelapse mortality (NRM) rates for the HID transplant group were 20.3% and 15.6%, respectively. In addition, there were no differences in OS, DFS, CIR, and NRM between the HID and MRD groups. Multivariate analysis showed that imatinib resistance was a significant factor influencing DFS and CIR in HID transplant patients. Haploidentical HSCT for the treatment of Ph+ ALL achieves promising long-term survival, which is comparable with that of HLA-MRD HSCT. Imatinib resistance is a negative predictor of relapse and DFS after allo-HSCT. (C) 2015 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.

语种英语
WOS记录号WOS:000354667900019
项目编号81230013 ; Z141100000214011 ; 81170483
资助机构Natural Science Foundation of China ; Beijing Science &amp ; Technology Program ; Nature Science Foundation of China
引用统计
被引频次:11[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/59601
专题北京大学第二临床医学院_血液科
医学人文研究院/公共教学部_哲学与社会科学系
作者单位Peking Univ, Inst Hematol, Peoples Hosp, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Chen, Huan,Liu, Kai-yan,Xu, Lan-ping,et al. Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION,2015,21(6):1110-1116.
APA Chen, Huan.,Liu, Kai-yan.,Xu, Lan-ping.,Chen, Yu-hong.,Han, Wei.,...&Huang, Xiao-jun.(2015).Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION,21(6),1110-1116.
MLA Chen, Huan,et al."Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia".BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 21.6(2015):1110-1116.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Chen, Huan]的文章
[Liu, Kai-yan]的文章
[Xu, Lan-ping]的文章
百度学术
百度学术中相似的文章
[Chen, Huan]的文章
[Liu, Kai-yan]的文章
[Xu, Lan-ping]的文章
必应学术
必应学术中相似的文章
[Chen, Huan]的文章
[Liu, Kai-yan]的文章
[Xu, Lan-ping]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。